NO- and Haem-Independent Soluble Guanylate Cyclase Activators
- 1 January 2009
- book chapter
- Published by Springer Nature
- No. 191,p. 309-339
Abstract
Oxidative stress, a risk factor for several cardiovascular disorders, interferes with the NO/sGC/cGMP signalling pathway through scavenging of NO and formation of the strong intermediate oxidant, peroxynitrite. Under these conditions, endothelial and vascular dysfunction develops, culminating in different cardio-renal and pulmonary-vascular diseases. Substituting NO with organic nitrates that release NO (NO donors) has been an important principle in cardiovascular therapy for more than a century. However, the development of nitrate tolerance limits their continuous clinical application and, under oxidative stress and increased formation of peroxynitrite foils the desired therapeutic effect. To overcome these obstacles of nitrate therapy, direct NO- and haem-independent sGC activators have been developed, such as BAY 58-2667 (cinaciguat) and HMR1766 (ataciguat), showing unique biochemical and pharmacological properties. Both compounds are capable of selectively activating the oxidized/haem-free enzyme via binding to the enzyme's haem pocket, causing pronounced vasodilatation. The potential importance of these new drugs resides in the fact that they selectively target a modified state of sGC that is prevalent under disease conditions as shown in several animal models and human disease. Activators of sGC may be beneficial in the treatment of a range of diseases including systemic and pulmonary hypertension (PH), heart failure, atherosclerosis, peripheral arterial occlusive disease (PAOD), thrombosis and renal fibrosis. The sGC activator HMR1766 is currently in clinical development as an oral therapy for patients with PAOD. The sGC activator BAY 58-2667 has demonstrated efficacy in a proof-of-concept study in patients with acute decompensated heart failure (ADHF), reducing pre- and afterload and increasing cardiac output from baseline. A phase IIb clinical study for the indication of ADHF is currently underway.Keywords
This publication has 114 references indexed in Scilit:
- Infarct limitation by a protein kinase G activator at reperfusion in rabbit hearts is dependent on sensitizing the heart to A2b agonists by protein kinase CAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Probing the presence of the ligand‐binding haem in cellular nitric oxide receptorsBritish Journal of Pharmacology, 2008
- Heme oxygenase-1 induction depletes heme and attenuates pulmonary artery relaxation and guanylate cyclase activation by nitric oxideAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Cyclic GMP and protein kinase‐G in myocardial ischaemia‐reperfusion: opportunities and obstacles for survival signalingBritish Journal of Pharmacology, 2007
- Desensitization of soluble guanylyl cyclase, the NO receptor, by S-nitrosylationProceedings of the National Academy of Sciences, 2007
- Inhaled NO as a therapeutic agentCardiovascular Research, 2007
- Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial KATP channels when administered at reperfusion following ischemia in rabbitsJournal of Molecular and Cellular Cardiology, 2007
- NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialNature Reviews Drug Discovery, 2006
- Nitric oxide activation of guanylyl cyclase in cells revisitedProceedings of the National Academy of Sciences, 2006
- NO‐independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomyBritish Journal of Pharmacology, 2006